GlobeNewswire Inc.T3·9mo ago
GNLX Genelux Corporation Common Stock
XNAS
2.05
Delayed
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
GNLX
$2.05
—
Key stats
$2.05
- 52-Week Range
- $1.97 – $8.54
- YTD
- -54.84%
- Straddle Price
- $1.23
- P/C Vol Ratio
- 0.43
- Market Cap
- $0.1B
- Open
- $2.04
- Day Range
- $1.97 – $2.35
- Volume
- 417,633
- Prev Close
- $2.07
Fair Value
MODEL: LONG
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 5.15% |
| Beta vs SPY | 0.73 |
| Cost of Equity (CAPM) | 8.82% (VRP-adj) |
| WACC | 8.83% |
| Volatility Risk Premium | +126.9pp (IV − HV30) |
| Effective Tax Rate | 21.0% |
| Rev. Growth (YoY, DCF input) | +3.0% |
| DCF Horizon | 10 years explicit + fade |
| Forward Tilt (NTM/TTM) | ×1.03 (applied to P/E, EV/EBITDA, P/S) |
| Free Cash Flow (TTM) | $-0.0B |
| Return on Equity (TTM) | -220.9% |
| Book / Price | 18.9% |
| Gross Margin (TTM) | 100.0% |
| FCF Margin (TTM) | -358537.5% |
| Debt / Equity | 0.00 |
| Quality Score | 2/6 — normal (10y DCF) |
| SMA 50 | $2.55 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $2.47 |
| Bollinger Width / SMA20 | 722.1% (drives anchor stability) |
| Net Debt | $-0.0B |
| Market Cap | $0B |
Peers used for multiples: ABBV, ABT, AZN, JNJ, LLY, MRK, NVO, NVS
60-Day Conviction
44%
20-Day Fair Value
≈ by Nov 20, 2026
$2.06
α +0.3%
rank 47%
conviction
18%
40-Day Fair Value
≈ by Dec 21, 2026
$2.10
α +2.2%
rank 54%
conviction
68%
60-Day Fair Value
≈ by Jan 19, 2027
$2.08
α +1.2%
rank 50%
conviction
44%
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | n/a | 0% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | n/a | 0% | median 43.2× · 7 peers |
| Peer EV/EBITDA | n/a | 0% | median 23.9× · 7 peers |
| Peer P/B | $3.14 | 50% | median 8.0× · 6 peers |
| Peer P/S | $0.00 | 50% | median 6.4× · 7 peers |
| Market Anchor (SMA50) | $2.55 | 0% | stability 0% (BB-width) |
| Options Expected (B-L 30d) | n/a | 0% |
As of 2026-10-22 · updated
Related
About
- Industry (SIC)
- PHARMACEUTICAL PREPARATIONS (2834) · industry map
- Exchange
- XNAS
- Market Cap
- $0.1B
- Employees
- 26
- List Date
- 2023-01-26
- CIK
- 0001231457
- Next Earnings
- 2026-11-04 (Pre-Market)
- EPS Forecast
- ($0.20) (2 est.)
- Headquarters
- Westlake Village, CA
- Homepage
- https://www.genelux.com
Genelux Corp is a late-stage biopharmaceutical firm focused on developing oncolytic viral immunotherapies for cancer. Its pipeline includes clinical and preclinical candidates designed to target tumor cells and stimulate an immune response against tumor-specific antigens. The company is focused on the development of next-generation oncolytic viral immunotherapies that are designed to generate a personalized multi-prong attack to overwhelm a tumor's sophisticated defense mechanisms.
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|
| Jan | -6.87% | -28.75% | 63.90% | -41.54% | -3.32% |
| Feb | 158.60% | -30.94% | 18.41% | 9.16% | 38.81% |
| Mar | 64.14% | -11.55% | -26.03% | -17.12% | 2.36% |
| Apr | -12.36% | -40.65% | 3.46% | 4.30% | -11.31% |
| May | 8.76% | -17.38% | -0.21% | 11.31% | 0.62% |
| Jun | 12.83% | -30.60% | 17.14% | 1.35% | 0.18% |
| Jul | -32.03% | 5.98% | 19.79% | 0.68% | -1.40% |
| Aug | 17.95% | 10.71% | -5.13% | -12.25% | 2.82% |
| Sep | 6.06% | 13.94% | 24.63% | -2.69% | 10.48% |
| Oct | -41.37% | 42.48% | 83.64% | -19.05%* | 16.43% |
| Nov | -24.73% | -16.20% | -32.52% | -- | -24.48% |
| Dec | 5.10% | -16.90% | -11.02% | -- | -7.61% |
| Total | 67.66% | -80.35% | 171.14% | -56.69% | 25.44% |
* Only 4 year(s) of data available.
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $2.45
SMA 50: $2.54
SMA 200: $2.72
Current: $2.04
EMA 12: $2.36
EMA 26: $2.45
MACD: -0.0856 | Signal: -0.0403
BEARISH
ADX (14): 15.92
RANGE
+DI: 11.80
−DI: 27.58
Momentum Oscillators
RSI (14): 31.22
NEUTRAL
Stoch %K: 23.74
Stoch %D: 32.35
Williams %R: -89.86
Volume & Volatility
BB Upper: $2.74
BB Lower: $2.16
OVERSOLD
OBV: -6,995,291
Vol SMA 20: 297,772
Vol ROC: 61.13%
ATR: $0.18
True Range: $0.38
HV 20: 81.6%
HV 30: 74.4%
HV 60: 69.3%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-10-23T00:00:00 – 2026-10-21T00:00:00
AI Analysis
LLM Stock Analysis Report
Executive Summary
BULLISH (Confidence Level: 7/10)
Key drivers:
- Bullish MACD signal with a strong momentum indicator
- Recent price action has reached the upper Bollinger Band, indicating overbought conditions
- Options market sentiment is bullish, pricing in a $2.33 move by expiration
Primary risks:
- Overbought RSI and stochastic indicators suggest potential for near-term pullback
- Volatility is above average, which may amplify price movements
Investment thesis: GNLX has strong technical momentum, driven by its recent price appreciation. While the stock may be overbought in the short term, its bullish MACD signal suggests a continued uptrend.
Recent news sentiment impact: No recent news headlines are available, but the lack of significant news events may have contributed to the stock's recent volatility.
Technical Analysis
Trend Direction: Short-term (1-4 weeks) - Bullish; Medium-term (1-3 months) - Bullish; Long-term (3-12 months) - Neutral
Support/Resistance Levels:
- Upper Bollinger Band: $5.20
- Middle Bollinger Band: $4.39
- Lower Bollinger Band: $3.57
Momentum Signals:
- RSI (14): 65.42 (neutral)
- MACD: Bullish signal with a strong momentum indicator
- Bollinger Bands: Price is touching the upper band, indicating overbought conditions
News & Sentiment Analysis
Recent Headlines Summary: No recent news headlines are available.
Sentiment Assessment: Neutral sentiment due to lack of significant news events.
Catalyst Identification: None identified.
Market Narrative: The market narrative is neutral, with no dominant theme or trend.
Risk & Volatility Assessment
Beta Interpretation: GNLX has a beta of 1.01, indicating that it moves in tandem with the broader market.
Volatility Regime: Current volatility is above average, which may amplify price movements.
Options Market Signals:
- IV Rank: Low (4.2%)
- Put/Call Volume Ratio: Bullish sentiment (0.00)
- Open Interest: 62 calls vs 0 puts
Market Context & Positioning
Sector Performance: GNLX is outperforming its sector, with a relative strength of 1.12.
Institutional Activity: Institutional interest is moderate, with a volume flow of 7 calls vs 0 puts.
Correlation Analysis: GNLX has a correlation coefficient of 0.20 with the broader market (SPY).
Key Levels & Action Items
- Critical Price Levels:
- Upper Bollinger Band: $5.20
- Middle Bollinger Band: $4.39
- Lower Bollinger Band: $3.57
- Breakout/Breakdown Levels:
- Short-term breakout above $5.20 could trigger further buying interest
- Downtrend triggered by a breakdown below $3.57
- Time-Sensitive Catalysts: None identified.
- Risk Management:
- Set stop-loss levels at the lower Bollinger Band ($3.57) to mitigate potential losses
- Consider scaling into long positions as the stock approaches the upper Bollinger Band ($5.20)
Note: This analysis is based on the provided data and does not account for any external factors that may affect the stock's performance.
Generated
News
All GNLX news →
GlobeNewswire Inc.T3·9mo ago
GlobeNewswire Inc.T3·25mo ago
GlobeNewswire Inc.T3·27mo ago
BenzingaT3·29mo ago
GlobeNewswire Inc.T3·29mo ago
GlobeNewswire Inc.T3·29mo ago
GlobeNewswire Inc.T3·29mo ago
Zacks Investment ResearchT3·30mo ago
Zacks Investment ResearchT3·30mo ago
Showing 1–10 of 50
Page 1 of 5
Earnings History
1 of 1 under expected move
Avg Expected Move
75.19%
Avg Actual Move
12.60%
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2025-03-25 | Pre-Market | 75.19% | 12.60% | 0.17x | Within |
Earnings calendar: this week’s reports with expected vs actual moves →
GNLX Options Activity & IV Rank
Volatility Metrics
Current IV: —
7-DTE IV: —
Expected Move: $1.23
7-DTE Move: $1.23
Days to Exp: 29 (2026-11-20)
Options Flow
Call Volume: 7
Put Volume: 3
P/C Volume: 0.429
BULLISH
Call OI: 1,006
Put OI: 237
P/C OI: 0.236
Total OI: 1,243
ATM Options Pricing
ATM Call: $0.38
ATM Put: $0.85
Call %: 18.2%
Put %: 41.4%
Chain Summary
Chain Volume: 3,913
Chain OI: 10,115
Last Updated: 10/22/2026
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Dealer Positioning
TYPICAL γ
Estimated net dealer gamma is at the 57th percentile of this name's own daily history, within its typical range. This describes current positioning; it is not a forecast or a trading signal.
Gamma percentile
57%
vs own history
GEX tilt
+0.85
OI-weighted, today
Vanna tilt
+0.83
δ-sensitivity to IV
Charm tilt
-0.92
δ-decay vs time
Vanna tilt +0.83: the estimated dealer exposure leans positive, so the modeled hedge would shift noticeably if implied volatility changed.
Charm tilt -0.92: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably as time passes and options approach expiry.
? What is this?
· 4 ATM contracts, 2k total OI
Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.
Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.
Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.
This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
No data
30 DTE / 10d
—
—
pts
EXTREME
ATM 240.0% / Wing —
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Enter a ticker to render the implied volatility surface.
Volatility Smile
Enter a ticker to render the implied volatility smile.
IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)$1.23Oct 22
Beta Analysis
Risk Metrics
Beta: 2.0664
Alpha: -110.67%
Correlation: 0.3386
R-Squared: 11.5%
Stock Volatility: 77.7%
Market Volatility: 12.7%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
High volatility - stock moves more than market
High volatility - stock moves more than market
Beta & Alpha Over Time
Notable investors who own GNLX
3 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Renaissance Technologies Hedge fund Jim Simons | $317K | #2757 of 3138 | +762.5% | 13F | |
| Citadel Hedge fund Ken Griffin | $257K | #5229 of 6285 | new | 13F | |
| Point72 Hedge fund Steve Cohen | $71K | #1858 of 1945 | new | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
GNLX Institutional Ownership (13F)
Latest filings — 2026-09-30
? 13F Guide
Diluted shares outstanding: 41,236,021 (as of 2026-06-30)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
1 filers$116.79K notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | GROUP ONE TRADING LLC Custodian | $116.79K | 100.00% | 2026-06-30 |
| # | Filer | Notional Value | % of Total | Period |
|---|
GNLX Insider Trading (Form 4)
Latest: 2026-09-02Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-09-02 | Yong Yu | Chief Scientific Officer | Sell (S) | −9,683 | $2.75 | -$26.7K | EDGAR |
| 2026-09-02 | Thomas Zindrick | President and CEO | Sell (S) | −34,463 | $2.67 | -$91.9K | EDGAR |
| 2026-09-02 | Joseph Cappello | Chief Technical Officer | Sell (S) | −10,257 | $2.74 | -$28.1K | EDGAR |
| 2026-08-04 | Yong Yu | Chief Scientific Officer | Sell (S) | −653 | $2.94 | -$1.9K | EDGAR |
| 2026-08-04 | Thomas Zindrick | President and CEO | Sell (S) | −3,023 | $2.95 | -$8.9K | EDGAR |
| 2026-08-04 | Joseph Cappello | Chief Technical Officer | Sell (S) | −653 | $2.95 | -$1.9K | EDGAR |
| 2026-07-02 | John W Smither | Director | Sell (S) | −12,000 | $2.91 | -$34.9K | EDGAR |
| 2026-06-18 | Thomas Zindrick | President and CEO | Award (A) | +730,601 | — | EDGAR | |
| 2026-06-18 | John Thomas | Director | Award (A) | +28,409 | — | EDGAR | |
| 2026-06-18 | Eric Groen | General Counsel | Award (A) | +233,957 | — | EDGAR | |
| 2026-06-18 | Matthew Pulisic | Chief Financial Officer | Award (A) | +278,906 | — | EDGAR | |
| 2026-06-18 | Joseph Cappello | Chief Technical Officer | Award (A) | +174,841 | — | EDGAR | |
| 2026-06-18 | James L Tyree | Director | Award (A) | +28,409 | — | EDGAR | |
| 2026-06-18 | Mary Mirabelli | Director | Award (A) | +28,409 | — | EDGAR | |
| 2026-06-18 | Yong Yu | Chief Scientific Officer | Award (A) | +119,318 | — | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
GNLX Insider Holdings
12 insiders · @ $2.04
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Thomas Zindrick | President and CEO | 1,426,427 | $2.91M | -$447.1K | 17 | 2026-09-02 |
| 2 | John Thomas | Director | 501,193 | $1.02M | -$454.5K | 15 | 2026-06-18 |
| 3 | Joseph Cappello | Chief Technical Officer | 318,480 | $649.7K | -$154.4K | 16 | 2026-09-02 |
| 4 | Matthew Pulisic | Chief Financial Officer | 278,906 | $569.0K | $0 | 2 | 2026-06-18 |
| 5 | Yong Yu | Chief Scientific Officer | 258,688 | $527.7K | -$3.27M | 27 | 2026-09-02 |
| 6 | Eric Groen | General Counsel | 233,957 | $477.3K | $0 | 2 | 2026-06-18 |
| 7 | Mary Mirabelli | Director | 102,693 | $209.5K | $0 | 7 | 2026-06-18 |
| 8 | James L Tyree | Director | 96,483 | $196.8K | -$132.0K | 11 | 2026-06-18 |
| 9 | John W Smither | Director | 91,403 | $186.5K | -$53.6K | 8 | 2026-07-02 |
| 10 | Lourie S. Zak | Chief Financial Officer | 82,452 | $168.2K | -$4.9K | 5 | 2024-12-20 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
GNLX Board & Officers
As of SEC filings through Sep 2, 2026Directors 4
- James L Tyree · since Jan 25, 2023
- John Thomas · since Jan 25, 2023
- Mary Mirabelli · since Jan 25, 2023
- John W Smither · since Sep 11, 2023
Officers 7
- Thomas Zindrick · President and CEO · since Jan 25, 2023
- Matthew Pulisic · Chief Financial Officer · since Jan 30, 2025
- Joseph Cappello · Chief Technical Officer · listed since Aug 2025
- Jason Litten · Chief Medical Officer · since Jan 2, 2026
- Yong Yu · Chief Scientific Officer · listed since May 2026
- Eric Groen · General Counsel & Secretary · since Jul 1, 2025
- Ralph Smalling · Head of Regulatory · since Jun 30, 2023
Changes in the last 10 years (29)
| May 12, 2026 | Yong Yu listed as Chief Scientific Officer (previously SVP, Clinical Development) in SEC filings |
| Jan 2, 2026 | Jason Litten became Chief Medical Officer |
| Dec 30, 2025 | The company announced the departure of Paul Scigalla as Chief Medical Officer in an SEC filing |
| Dec 11, 2025 | Thomas Zindrick no longer listed as a director in SEC filings |
| Aug 29, 2025 | Yong Yu listed as SVP, Clinical Development (previously VP, Clinical Trial Operations) in SEC filings |
| Aug 29, 2025 | Joseph Cappello listed as Chief Technical Officer (previously VP, Pharmaceutical Development) in SEC filings |
| Jul 1, 2025 | Eric Groen became General Counsel & Secretary |
| Jan 30, 2025 | Matthew Pulisic became Chief Financial Officer |
| Jan 29, 2025 | The company announced the departure of Lourie S. Zak as Chief Financial Officer in an SEC filing |
| Sep 23, 2024 | The company announced the departure of Caroline Jewett as Head of Quality in an SEC filing |
| Sep 13, 2024 | Aladar Szalay reported in an SEC filing no longer being a 10% owner |
| Nov 21, 2023 | The company announced the departure of Doug Samuelson as Chief Financial Officer in an SEC filing |
| Sep 11, 2023 | John W Smither became a director |
| Aug 28, 2023 | Lourie S. Zak became Chief Financial Officer |
| Jun 30, 2023 | Ralph Smalling became Head of Regulatory |
| Jun 30, 2023 | Caroline Jewett became Head of Quality |
| Jan 25, 2023 | Yong Yu became VP, Clinical Trial Operations |
| Jan 25, 2023 | Thomas Zindrick became a director |
| Jan 25, 2023 | Thomas Zindrick became President and CEO |
| Jan 25, 2023 | Sean Ryder became General Counsel |
| Jan 25, 2023 | Qian Zhang became Associate VP, Research |
| Jan 25, 2023 | Paul Scigalla became Chief Medical Officer |
| Jan 25, 2023 | Mary Mirabelli became a director |
| Jan 25, 2023 | Joseph Cappello became VP, Pharmaceutical Development |
| Jan 25, 2023 | John Thomas became a director |
| Jan 25, 2023 | James L Tyree became a director |
| Jan 25, 2023 | Gabe Woodward became a director |
| Jan 25, 2023 | Doug Samuelson became Chief Financial Officer |
| Jan 25, 2023 | Aladar Szalay became a 10% owner |
Not reported recently (3)
- Sean Ryder · Last reported as General Counsel in an SEC filing dated May 13, 2025
- Gabe Woodward · Last reported as a director in an SEC filing dated May 2, 2023
- Qian Zhang · Last reported as Associate VP, Research in an SEC filing dated May 2, 2023
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
GNLX Proposed Insider Sales (Form 144)
Latest: 2026-07-01
? Form 144 Guide
Last 30d:
0 filings
· Last 90d:
0 filings
What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.
How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.
10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.
"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.
Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.
| Filed | Filer | Role | Shares | Notice Value | Planned Sale | Broker | Plan | Link |
|---|---|---|---|---|---|---|---|---|
| 2026-07-01 | JOHN SMITHER | Director | 12,000 | $34.9K | 2026-07-01 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| 2026-06-01 | JOHNNY THOMAS | Officer | 10,000 | $30.5K | 2026-06-01 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-03-02 | JOHNNY THOMAS | Officer | 10,000 | $29.8K | 2026-03-02 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2025-12-01 | JOHNNY THOMAS | Director | 10,000 | $55.6K | 2025-12-01 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2024-12-30 | JAMES L TYREE | Director | 3,460 | $8.5K | 2024-12-30 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| 2024-09-11 | JAMES L TYREE | Director | 1,730 | $4.3K | 2024-09-11 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2024-09-06 | SZALAY 2010 RETAINED ANNUITY TRUST | 10% Stockholder | 140,000 | $392.0K | 2024-09-09 | Ty W, Schmidt Merrill | — | EDGAR |
| 2024-08-22 | SZALAY 2010 RETAINED ANNUITY TRUST | 10% Stockholder | 400,000 | $872.0K | 2024-08-23 | Ty Schmidt Merrill | — | EDGAR |
| 2024-04-15 144/A | SZALAY 2010 RETAINED ANNUITY TRUST | 10% Stockholder | 494,744 | $2.10M | 2024-04-15 | Ty W. Schmidt | — | EDGAR |
| 2023-12-15 | YONG YU | Officer | 32,535 | $428.2K | 2023-12-15 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
ETF Holders
3 ETFs hold GNLX
3 shown · $4.52M total exposure · 0.03% AUM-weighted avg weight
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Trailing P/E
—
TTM Diluted EPS
$-0.86
TTM Revenue
$8.00K
TTM Net Income
$-35.60M
TTM Op. Cash Flow
$-25.28M
Quarterly figures (12 quarters)
| Quarter | Period End | Revenue | Net Income | Diluted EPS | Op. Cash Flow |
|---|---|---|---|---|---|
| Q2 '26 | 2026-06-30 | $0.00 | $-9.47M | $-0.21 | $-6.44M |
| Q1 '26 | 2026-03-31 | — | $-8.93M | $-0.20 | $-6.06M |
| Q4 '25 | 2025-12-31 | $8.00K | $-9.25M | $-0.24 | $-6.20M |
| Q3 '25 | 2025-09-30 | — | $-7.95M | $-0.21 | $-6.58M |
| Q2 '25 | 2025-06-30 | $0.00 | $-7.46M | $-0.20 | $-7.06M |
| Q1 '25 | 2025-03-31 | — | $-7.49M | $-0.21 | $-5.43M |
| Q4 '24 | 2024-12-31 | $0.00 | $-8.98M | $-0.26 | $-4.30M |
| Q3 '24 | 2024-09-30 | — | $-6.47M | $-0.19 | $-5.75M |
| Q2 '24 | 2024-06-30 | — | $-6.58M | $-0.22 | $-6.82M |
| Q1 '24 | 2024-03-31 | $8.00K | $-7.85M | $-0.29 | $-4.35M |
| Q4 '23 | 2023-12-31 | $0.00 | $-6.77M | $-0.25 | $-6.91M |
| Q3 '23 | 2023-09-30 | — | $-5.34M | $-0.20 | $-3.36M |
Q2 2026 • period ending 2026-06-30 • filed 2026-08-13
Valuation
Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.
Price Multiples
- P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
- P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
- P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
- EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
- EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
- ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
- ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
- Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
- FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
- Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
- Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
- Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
- Multiples expanding while earnings are flat = sentiment-driven rally.
- Multiples compressing while earnings grow = value coming from fundamentals.
P/E
—
P/B
5.22
P/S
10515.19
EV/EBITDA
—
EV/Sales
9367.19
ROE
-220.9%
ROA
-135.8%
Div Yield
0.00%
FCF Yield
-30.05%
Debt/Equity
0.00
Current Ratio
—
Market Cap
$84.12M
as of 2026-10-22
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
4.36M
SI % of Float
11.40%
Days to Cover
20.43
Short Vol Ratio
58.0%
Free Float
38.26M
Float %
85.3%
Short interest 2026-09-30 • Short volume 2026-10-21 • Float 2026-08-14